Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The Randox ConcizuTrace ELISA is used to determine the concentration in blood of Novo Nordisk's Alhemo (concizumab-mtci) to aid dose adjustments.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused notable weight loss in mice ...

Novo Nordisk's sales have been growing fast thanks to GLP-1 medicines like Ozempic for diabetes and Wegovy for weight management. In 2024, revenue increased by 25% year over year to 290 billion ...

Ozempic maker Novo Nordisk NOVO.B-0.94%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

The federal agency and Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic, said this week that they had learned about "several hundred units" of the drug that made it onto the market ...